Wednesday, July 8, 2026

Intelligence · Clinical Development

Pipeline search results

Programs matching “glatiramer acetate” across our ClinicalTrials.gov index — phase, modality, sponsor, and trial IDs.

Matching programs 14
Total indexed 20,548
Sponsors 1,769

Quick answer

Showing 14 pipeline programs matching "glatiramer acetate" from NovaPharmaNews Clinical Development Intelligence — phase, modality, sponsor, and ClinicalTrials.gov trial IDs.

Refine search

14 results for “glatiramer acetate” Back to intelligence hub

Search results

  1. Glatiramer Acetate

    Teva Pharma GmbH

    Optic Neuritis

    phase 3 small molecule completed

    1 trial
  2. Glatiramer Acetate (DB)

    Teva Pharma GmbH

    Multiple Sclerosis

    phase 3 small molecule completed

    1 trial
  3. Glatiramer Acetate (GA) 40 mg

    Teva Pharma GmbH

    Relapsing Remitting Multiple Sclerosis

    phase 3 small molecule completed

    1 trial
  4. Glatiramer Acetate 20 mg/0.5 mL

    Teva Pharma GmbH

    Multiple Sclerosis

    phase 3 small molecule completed

    1 trial
  5. Glatiramer acetate (GA)

    Teva Pharma GmbH

    Relapsing Remitting Multiple Sclerosis

    phase 3 small molecule completed

    1 trial
  6. 40 mg glatiramer acetate

    Teva Pharma GmbH

    Amyotrophic Lateral Sclerosis

    phase 2 small molecule completed

    1 trial
  7. Glatiramer Acetate, N-Acetylcysteine

    Teva Pharma GmbH

    Relapse Remitting Multiple Sclerosis

    phase 2 small molecule completed

    1 trial
  8. glatiramer acetate

    Teva Pharma GmbH

    Crohns Disease

    phase 2 small molecule active

    1 trial
  9. glatiramer acetate 20 mg

    Teva Pharma GmbH

    Relapsing Remitting Multiple Sclerosis

    phase 2 small molecule completed

    1 trial
  10. glatiramer acetate 20 mg

    Teva Pharma GmbH

    Relapse-Remitting Multiple Sclerosis

    phase 2 small molecule completed

    1 trial
  11. glatiramer acetate with minocycline

    Teva Pharma GmbH

    Relapse Remitting Multiple Sclerosis

    phase 2 small molecule completed

    1 trial
  12. Glatiramer Acetate

    Teva Pharma GmbH

    Relapsing Remitting Multiple Sclerosis

    approved small molecule terminated

    5 trials
  13. glatiramer acetate

    Teva Pharma GmbH

    Multiple Sclerosis

    approved small molecule active

    2 trials
  14. glatiramer acetate injection with oral cetirizine hydrochloride

    Teva Pharma GmbH

    Multiple Sclerosis

    approved small molecule completed

    1 trial

Frequently asked questions

What is the Clinical Development Intelligence Platform?

It is NovaPharmaNews pipeline intelligence hub covering 20,548 clinical development programs — not just a directory. It includes phase distribution dashboards, therapeutic area overviews, NDA/BLA watchlists, upcoming readouts, company pipeline rankings, competitive landscape maps, and personalized watchlists.

How does this compare to Evaluate Pharma or Citeline?

Like Evaluate Pharma and Citeline Trialtrove, we index ClinicalTrials.gov programs by sponsor, phase, and indication. Our platform adds cross-links to NovaPharmaNews company profiles, drug INN pages, patents, and congress readout calendars — improving crawl depth and reducing orphan program pages.

Where does pipeline data come from?

Program records derive from ClinicalTrials.gov and link to sponsor company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment decisions. See our data sources page for attribution.

Can I follow a company or program for updates?

Yes — use the watchlist forms on this page to follow sponsors, individual programs, disease clusters, or therapeutic areas. Alerts use the same subscription infrastructure as our events intelligence hub.